Don't Think Too Hard About Gum
At the turn of the 20th century, William Wrigley Jr. was bent on building an empire of gum, and as part of his extensive hustle, he managed to persuade the U.S. Department of War to include his products in soldiers' rations. His argument—baseless at the time—was that chewing gum had miraculous abilities to quench thirst, stave off hunger, and dissipate nervous tension. But he was right: Scientists have since found that gum chewing can indeed increase concentration, reduce the impulse to snack, alleviate thirst, and improve oral health.
Perhaps that's why people around the world have had the impulse to gnaw on tacky materials—roots, resins, twigs, blubber, tar made by burning birch bark—for at least 8,000 years. Today, gum is again being marketed as a panacea for wellness. You can buy gum designed to deliver energy, nutrition, stress relief, or joint health; scientists are even developing gums that can protect against influenza, herpes, and COVID. Ironically, this new era of chewing gum is manufactured with a distinctly modern ingredient, one not usually associated with wellness: plastic.
By the time Wrigley began his business venture, Americans had grown accustomed to chewing gum sold as candy-coated balls or packaged sticks. The base of these chewing gums was made from natural substances such as spruce resin and chicle, a natural latex that Aztecs and Mayans chewed for hundreds if not thousands of years. Unfortunately for 20th-century Americans, the chicozapote trees that exude chicle take a long time to grow, and if they are overtapped, they die. Plus, cultivated trees don't produce nearly as much chicle as wild trees, says Jennifer Mathews, an anthropology professor at Trinity University and the author of Chicle. In the 1950s, chicle harvesters began struggling to meet demand. So gum companies turned to the newest innovations in materials science: synthetic rubbers and plastics.
Today, most companies' gum base is a proprietary blend of synthetic and natural ingredients: If a packet lists 'gum base' as an ingredient, that gum most likely contains synthetic polymers. The FDA allows gum base to contain any of dozens of approved food-grade materials—substances deemed either safe for human consumption or safe to be in contact with food. Many, though, are not substances that people would otherwise think to put in their mouth. They include polyethylene (the most common type of plastic, used in plastic bags and milk jugs), polyvinyl acetate (a plastic also found in glue), and styrene-butadiene rubber (commonly used in car tires). The typical gum base contains two to four types of synthetic plastics or rubbers, Gwendolyn Graff, a confectionery consultant, told me.
Everything we love about gum today is thanks to synthetic polymers, Graff said. Polyvinyl acetate, for example, strengthens the bubble film. 'If you blow a bubble, and it starts to get holes in it and deflate, that's usually an indicator that it doesn't have polyvinyl acetate,' Graff said. Styrene-butadiene rubber creates a bouncy chewiness that makes gum more likely to stick to itself rather than to surfaces like your teeth. Polyethylene can be used to soften gum so it doesn't tire out your jaw. Gums with only natural polymers 'can feel like they're going to fall apart in your mouth,' Graff said.
Plastic gum, though, also falls apart, in a way: Gum chewing has been linked to microplastic ingestion. In a study published in December, U.K. researchers had a volunteer chew on a piece of gum for an hour, spitting into test tubes as they went. After an hour of gum chewing, the saliva collected contained more than 250,000 pieces of micro and nano plastics—comparable to the level of microplastics found in a liter of bottled water. In a study presented at a recent meeting of the American Chemical Society (which has not yet been peer-reviewed), a graduate student's saliva contained elevated microplastic levels after she chewed several commercially available gums, including natural ones. The research on gum chewing and microplastics is still limited—these two papers effectively represent analysis of just two people's post-chew saliva—but gum chewing has also been correlated with higher urine levels of phthalates, plastic-softening chemicals that are known endocrine disruptors.
Scientists are still learning about the health impacts of microplastic ingestion, too. Microplastics find their way into all kinds of foods from packaging or contamination during manufacturing, or because the plants and animals we eat absorb and ingest microplastics themselves. As a result, microplastics have been found in human livers, kidneys, brains, lungs, intestines, placentas, and breast milk, but exactly how our bodies absorb, disperse, and excrete ingested plastic is not very well studied, says Marcus Garcia, who researches the health effects of environmental contaminants at the University of New Mexico. Some research in mice and cultured cells hint that microplastics have the potential to cause damage, and epidemiological research suggests that microplastics are associated with respiratory, digestive, and reproductive issues, as well as colon and lung cancer. But scientists are still trying to understand whether or how microplastics cause disease, which microplastics are most dangerous to human health, and how much microplastic the body can take before seeing any negative effects.
The answer could affect the future of what we choose to eat—or chew. Ingesting tiny plastic particles might seem inevitable, but over the past 10 years or so, Americans have grown understandably fearful about bits of plastic making their way into our food, fretting about microwaving food in plastic containers and drinking from plastic bottles. Gum has, for the most part, not triggered those worries, but in recent years, its popularity had been dropping for other reasons. In a bid to reverse that trend, gum companies are marketing synthetic gum as a tool for wellness. Just like Wrigley, they are betting that Americans will believe in the power of gum to soothe nerves and heal ailments, and that they won't think too hard about what modern gum really is. For anyone worried about swallowing still more plastic, after all, gum is easy enough to avoid.
Article originally published at The Atlantic
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
32 minutes ago
- Associated Press
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob Jahr as Chief Executive Officer (CEO). Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' Chief Financial Officer (CFO) and interim CEO, will continue serving as CFO and as a member of the Board of Directors. 'We are very pleased to welcome Bob to the executive leadership team as we continue to execute on our path forward. Bob's experience, track record and deep understanding of the biopharmaceutical industry will be invaluable as we scale as a commercial entity. With our launch in Europe underway and potential U.S. Food and Drug Administration (FDA) approval in the coming months, we believe this appointment is timely and positions us to drive value for our stakeholders,' commented Faisal G. Sukhtian, Chairman of the Outlook Therapeutics Board of Directors. Mr. Jahr brings more than 20 years of experience in the biopharmaceutical industry building and leading commercial teams spanning therapeutic areas including rare disease, oncology, hematology, autoimmunology, neuroscience, cardiovascular and inflammation. Over the course of his career, he has led operational and commercial efforts for multiple billion dollar assets and franchises. 'LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) has the potential to truly transform the global retina market and offer a much-needed ophthalmic formulation of bevacizumab for wet AMD,' added Mr. Jahr. 'With the commercial launch underway in Europe and potential FDA approval in the U.S. in the near term, I am excited to join the team at such a pivotal time for Outlook Therapeutics. I look forward to adding the depth and breadth of my experience to Outlook Therapeutics and continue building momentum to position it as a leader in the ophthalmology market.' Mr. Jahr joins Outlook Therapeutics having most recently served as the Chief Commercial Officer for Sobi North America (NA), where he oversaw commercial strategy, planning and execution excellence, which includes accountability for all marketing, sales, operations and market access activities. During his tenure at Sobi NA, Mr. Jahr led the immunology and hematology franchises, and three global development asset teams focused on preparing for regulatory submission, life cycle management and launch. Prior to his role at Sobi NA he served as General Manager & Vice President Head of International Markets at UCB Pharma SA (UCB) where he managed the company's portfolio in markets including China, Japan, Brazil, AUS, Canada, Middle East and Latin America. He also served as VP Head of US Payer Value, Pricing, Strategy & Innovation at UCB where he was responsible for developing teams during a period of expansion and launches. Prior to UCB he held leadership roles in sales, marketing, operations, payor strategy, and market access at Amgen. Mr. Jahr holds a Master of Business Administration degree and a Bachelor of Science degree in Business Administration and Management from University of Montana. Inducement Grant Additionally, Outlook Therapeutics announced that the independent members of its Board of Directors approved the issuance of an option to purchase 800,000 shares of common stock to Mr. Jahr in accordance with Nasdaq Listing Rule 5635(c)(4), as a material inducement to Mr. Jahr's start of employment with Outlook Therapeutics. The option will be issued on July 1, 2025 with an exercise price per share equivalent to the closing price of Outlook Therapeutics' common stock on the date of grant. The option will vest over four years, with 25% of the shares subject to the option vesting on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the three years thereafter, subject to Mr. Jahr's continuous service through the applicable vesting date. About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD. In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as 'anticipate,' 'believe,' 'continue,' 'expect,' 'may,' 'plan,' 'potential,' 'will,' or 'would' the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, expectations concerning the therapeutic potential of ONS-5010/LYTENAVA™ as a treatment of wet AMD, Outlook Therapeutics' commercialization strategy, the market opportunity for ONS-5010/LYTENAVA™, expectations concerning decisions of regulatory bodies and the timing thereof, ONS-5010/LYTENAVA™'s potential as the first FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal indications, including wet AMD, in the United States and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, the sufficiency of Outlook Therapeutics' resources, unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions (including the long-term impacts of ongoing overseas conflicts, tariffs and trade tensions, fluctuations in inflation and interest rates and other economic uncertainty), as well as those risks detailed in Outlook Therapeutics' filings with the Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the SEC on December 27, 2024, the Quarterly Report on Form 10-Q for fiscal quarter ended March 31, 2025 and future quarterly reports Outlook Therapeutics files with the SEC. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. Investor Inquiries: Jenene Thomas Chief Executive Officer JTC Team, LLC T: 908.824.0775 [email protected]


Fox News
an hour ago
- Fox News
Chicago abortion clinic opens offering controversial third-trimester abortions
An abortion clinic in Chicago is now offering controversial third trimester abortion services to pregnant women. Abortion provider Hope Clinic, in Granite City, opened a second location in Chicago's Uptown neighborhood on June 2, advertising that it now offers "all-trimester" abortions. "Hope Clinic is now open in Chicago, IL, expanding our care through all trimesters! (And OMG we couldn't be more excited)," the clinic posted on Instagram. "Everyone deserves access to abortion care, whenever they need it. Because deciding and acting on what's best for you shouldn't be on anyone else's timeline." The clinic explains on its website that it offers surgical abortion procedures to women up to 34 weeks into their pregnancy. According to a report by The Chicago Tribune, the clinic is "the only standalone clinic in the Midwest to offer often-controversial terminations in the third trimester and among only a handful that do so nationwide." Under Illinois law, women can get an abortion for any reason up to the point of fetal viability, around 24 weeks. Abortions are allowed later in pregnancy if the mother's health or well-being, "including, but not limited to, physical, emotional, psychological, and familial health and age," is considered threatened by the pregnancy, according to the state's Reproductive Health Act. The clinic's website explained in a social media post some of the reasons why women might want to get "later abortions." Some women "don't know" they are pregnant until further along, while others "learn new information," such as a fetal anomaly diagnosis. Some women aren't able to "access care" earlier in their pregnancy, according to the post. Lastly, it says, some women "just don't want to be pregnant." "You get to change your mind and make decisions that are right for you. And they don't have to be on anyone else's timeline," the clinic's post reads. Dr. Erin King, Hope Clinic chief medical officer, told the Tribune that they would be following the law while ensuring as many people can access abortion as possible. "I want people to know that we are absolutely following the law, but that we make a really careful determination," she said. "And we want to provide access to as many people as we can within the law." At 34 weeks, a baby can weigh around 5 lbs and the pregnancy is considered "near-term." Over 90% of babies born after 28 weeks, the beginning of the third trimester, typically survive outside the womb, according to one 2022 study. According to a 2023 Gallup poll, majorities of Americans oppose legal abortion in the second (55%) and third (70%) trimesters. A local pro-life activist told the Tribune that he appreciated the clinic's transparency but believed that most people would consider abortions at this stage "brutality." "Almost everyone recognizes the brutality of an abortion that late in pregnancy," Eric Scheidler, executive director of the Chicago-based Pro-Life Action League, told the paper. "I think it's a common ground area we have with a lot of people. As alarming as it is for someone like me who cares about fetal life, life in the womb, and who cares about the fate of women who participate in the demise of their child, on another level I appreciate the honesty and openness. Because it allows us to have a frank conversation about what late-term abortion really is." Anne O'Connor, VP of Legal Affairs at pro-life organization The National Institute of Family and Life Advocates, told Fox News Digital that babies in the third trimester are "fully formed, unique human beings" and called abortions at this stage "especially gruesome and unnecessary." "This is a shameful situation and ironic that it is happening at a place called 'Hope.' There is no hope in that ghastly chamber - just despair and destruction," she told Fox News Digital. "The sad thing is that it is legal because the United States is one of the few countries in the world that does not put any limits on late term abortions. We are joined by the likes of China, Vietnam and South Korea in destroying human beings in this horrific and appalling manner. The network of pregnancy centers in the U.S. is enormous and ready to help these women who feel abortion is their best option." Hope Clinic defended their services in a comment to Fox News Digital: "Hope Clinic provides compassionate abortion care throughout pregnancy, in full accordance with Illinois law. We need to ensure that people who experience health complications during pregnancy have access to a full range of treatment options. With abortion bans around the country forcing more people to delay their care and travel longer distances, expanding access to later abortion care is even more important. All people deserve access to high-quality health care throughout pregnancy without arbitrary restrictions, and we are committed to providing this care so our patients can make the best decisions for themselves and their families."


The Hill
an hour ago
- The Hill
Supreme Court's Medina ruling frees states to defund Planned Parenthood
The U.S. Supreme Court just delivered a major blow to the abortion industry with its ruling allowing states to defund abortion businesses like Planned Parenthood. In its 6-3 decision in Medina v. Planned Parenthood South Atlantic, the court confirmed that states get to decide who qualifies for Medicaid funding and can instead fund organizations that provide real, comprehensive health care. For seven years, South Carolina Gov. Henry McMaster (R) has defended his state's policy against using tax dollars to fund abortion providers. This spring, my firm, Alliance Defending Freedom, represented South Carolina at the Supreme Court, receiving support from a broad coalition that included the U.S. government and 18 states. We argued that states should be free to direct Medicaid funds away from the abortion industry and toward real health care providers that offer women a wide range of services. The court's ruling last week allows South Carolina to do just that. Medicaid exists to help low-income Americans get the medical care they need. But abortion giants like Planned Parenthood focus instead on ending unborn life and distributing puberty blockers and cross-sex hormones to gender-confused children. That is not medical care. They also don't need public dollars, as they are already flush with cash. Planned Parenthood, for instance, received $3.2 billion from taxpayers over a five-year period. That's on top of the hundreds of millions more it receives from private donors every year. And since Roe v. Wade was reversed in 2022, it's had a fundraising boom, amassing over $2.5 billion in net assets. Despite such revenues, Planned Parenthood has proved to be a poor steward of its resources. In February, The New York Times reported that over the last five years, Planned Parenthood's 'national office has distributed more than $899 million to affiliates to help them deliver care, but none of it went directly to medical services.' Where did it go? According to The Times, much of it went to pro-abortion politicking and legal costs. Meanwhile, women's health suffered. From 2022 to 2023, women's preventative-care visits to Planned Parenthood fell by 31 percent — even as it performed a record-high 402,000 abortions. Since 2010, its cancer screening and prevention services have fallen by 71 percent, including a 72 percent drop for breast exams and 74 percent for pap tests. The Times also revealed multiple examples of botched care, aging equipment, poorly trained staff, and a 'chaotic' and 'toxic' culture at Planned Parenthood. One former employee described its facilities as a 'conveyor belt' where women were often given the wrong medications, taken to the wrong rooms, and prepped for the wrong procedures as employees 'scrambled to move people in and out.' Women deserve better than this, and taxpayers certainly shouldn't have to fund it. Beyond offering substandard care, Planned Parenthood also preys on children. It is now the nation's second-largest provider of dangerous gender-transition drugs something it openly advertises — and it gives these drugs to minors. Not surprisingly, when South Carolina acted to shield children from these drugs over against Planned Parenthood's political efforts, the abortion giant was 'outraged.' Consensus has turned sharply against these medical experiments on minors, both here and around the world. Seven in 10 Americans now oppose giving children gender-transition drugs. No state should be forced to fund groups that do so. Most Americans also oppose using their tax dollars to support abortion. This Supreme Court ruling vindicates them. The Medicaid dollars that flowed to Planned Parenthood, while not directly funding abortions, freed up vast amounts of other funds that can then be used for abortions. Because of this ruling, South Carolina taxpayers no longer have to line the pockets of Planned Parenthood, its substandard care for women or gender-transition drugs for children. They are instead free to support the nearly 200 clinics across their state that offer high-quality, comprehensive care to women. And other states are free to do the same. Kristen Waggoner is CEO and president of Alliance Defending Freedom.